PROGRAM CHAIR
Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice Chair, Clinical Operations
Department of Neurology
Beth Israel Deaconess Medical Center
Boston, Massachusetts
SPEAKER
Miriam L. Freimer, MD
Professor of Neurology
The Ohio State University
Columbus, Ohio
PROGRAM OVERVIEW
This educational program provides a comprehensive review of FcRn antagonists for the management of generalized myasthenia gravis (gMG). The program explores the mechanism of action of this therapeutic class, alongside an analysis of efficacy and safety data derived from the pivotal clinical trials that supported their regulatory approval. Through case studies, participants will gain insights into the practical application of FcRn antagonists in clinical settings, enhancing their ability to integrate these therapies into patient care.
TARGET AUDIENCE
This activity is designed for neurologists, neuromuscular specialists, nurse practitioners, and physician assistants engaged in the management of patients with generalized myasthenia gravis (gMG).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the MoA and the potential for FcRn antagonists to address remaining therapeutic unmet needs for appropriate patients with gMG
- Utilize clinical efficacy and safety data for FcRn antagonists, along with best practices for dosing and safety profile optimization, for the development of individualized treatment plans for patients with gMG
- Adopt SDM approaches to incorporate patient preferences into gMG treatment plans and facilitate continued open communication
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Pushpa Narayanaswami, MD, FAAN | Royalties: Springer Nature Consulting fees: argenx, Amgen, Alexion, CVS Caremark, Dianthus Therapeutics, ImmuneAbs, Immunovant, and Johnson & Johnson, Cartesian Therapeutics, EMD-Serono, UCB, and Viridian Therapeutics Contracted research: Alexion Data safety monitoring boards: argenx, NMD Pharma, and Sanofi |
| Miriam L. Freimer, MD | Consulting: argenx, Cartesian Therapeutics, Johnson & Johnson, NMD Pharma Research: argenx, Avidity Biosciences, COUR Pharmaceuticals, U.S. Department of Defense, National Institutes of Health (NIH), NMD Pharma, Novartis, Syneos Health, Abcuro, UCB |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Melissa Carter, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Sarah Milano, RN, MSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 04, 2025
EXPIRATION DATE: December 04, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
